BioPharma Dive May 24, 2024
Ben Fidler

“In rare diseases, we need something now, not later,” said Peter Marks, head of the FDA office that reviews gene therapies, at a conference held Friday.

A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare diseases. But he didn’t drop any clues on where the agency stands on a coming decision to possibly broaden use of one of them, a Duchenne muscular dystrophy treatment the regulator cleared last year.

At a meeting hosted by the patient advocacy group CureDuchenne, Peter Marks, head of the FDA office that reviews gene therapies, said the agency’s thinking has changed in recent years to become more patient focused. That mindset has led it...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot
Q&A: How Will the FDA Panel's Decision on MDMA Impact the Future of Psychedelic Medicine?
FDA approves 1st adult vaccine for bacterial pneumonia
FDA Approves Pneumococcal 21-Valent Conjugate Vaccine Capvaxive
FDA tells providers to prepare for supply chain disruptions

Share This Article